Skip to main content

Table 4 Univariate and multivariate analyses of factors affecting overall survival

From: The change rate in serum nitric oxide may affect lenvatinib therapy in hepatocellular carcinoma

 

Univariate analysis

Multivariate analysis

Variable

 

HR (95% CI)

P value

HR (95% CI)

P value

CSRN

–

1.000

 

1.000

 

+

2.203 (1.253–3.873)

0.006

2.017 (1.130–3.599)

0.018

Age

<  70

1.000

   

≥ 70

1.690 (0.926–3.085)

0.088

  

Body weight (kg)

<  60

1.000

   

≥ 60

1.130 (0.652–1.960)

0.663

  

Barcelona Clinic Liver Cancer stage

B

1.000

   

C

1.071 (0.616–1.861)

0.808

  

Up to seven

In

1.000

   

Out

1.450 (0.838–2.510)

0.184

  

Metastatic disease

–

1.000

   

+

1.042 (0.576–1.886)

0.891

  

Previous therapy: Transcatheter treatment

–

1.000

   

+

1.203 (0.650–2.229)

0.556

  

Refractory to Transcatheter treatment

–

    

+

1.311 (0.596–1.520)

0.742

  

α-fetoprotein (ng/mL)

<  400

1.000

   

≥ 400

1.630 (0.920–2.885)

0.094

  

Albumin

≥ 3.2

1.000

 

1.000

 
 

<  3.2

2.866 (1.309–6.276)

0.008

2.401 (1.073–5.370)

0.033